RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation of issuance of duplicate share certificates as received by us from Link Intime India Private Limited, our Registrar and Transfer Agents, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation of our Letters dated April 25, 2023 and May 2, 2023, we would like to inform you that transcript of the Results Earnings Call for the Audited Financial Results for the quarter and year ended March 31, 2023, held on Tuesday, May 2, 2023, at 3.30 p.m. IST. has been made available on the Company's website at: https://www.rpglifesciences.com/website/earnings_call.php Kindly take the same on record and disseminate appropriately. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
n continuation of our Letters dated April 29, 2023 and May 02, 2023, we would like to inform you that audio recording of the Results Earnings Call for the Audited Financial Results for the year ended March 31, 2023, held today i.e. Tuesday, May 2, 2023, at 3.30 p.m. IST. has been made available on the Company's website at https://www.rpglifesciences.com/website/earnings_call.php Kindly take the same on record and disseminate appropriately. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Investor Presentation
In continuation of our Letter dated April 25, 2023, please find enclosed herewith Investor Presentation for the quarter and year ended March 31, 2023, for the Results Earnings call scheduled on Tuesday, May 2, 2023, at 3.30 p.m. IST. Kindly take the same on record and disseminate appropriately. Q4FY23 Quarterly & FY23 Annual Result Announced for RPG Life Sciences Ltd.
Pharmaceuticals company RPG Life Sciences announced Q4FY23 & FY23 results: Q4FY23: PBT up by 26% YoY for Q4FY23, maintaining the upward trajectory in EBITDA margins, which improved from 14.2% to 15.0% YoY Revenue from operations at Rs 118.49 crore registered a growth of 14% YoY for Q4FY23 FY23: For FY23, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 20.3% to 21.0% YoY Revenue from operations at Rs 512.81 crore registered a growth of 17% YoY for FY23 Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4 FY23, the company maintained its upward trajectory of overall robust performance by posting yet another strong result despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by a healthy 14% and 26% respectively YoY. EBITDA margins’ consistent upward trajectory has continued for the last 5 years, growing from 10.4% (FY19) to 15.9%(FY20) to 18.2% (FY21) to 20.3% (FY22) to 21.0% (FY23). The company continues to remain debt-free with the highest-ever net cashflow generated from operations in full-year FY23. Its domestic formulations business, the biggest contributor to the company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth, while emerging as another growth driver for the company, registering healthy growth in both sales and profits. The company is investing in plant upgradation and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, are helping us to improve our margins consistently. We are well on course to implement our transformation agenda to achieve our strategic goals.” Result PDF
Multibagger pharma stock up over 230% in 3 years, Board declares 150% dividend
RPG Life Sciences, a small-cap firm, closed on Friday with a market valuation of 1,382.08 Cr. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Audited Financial Results for the quarter and year ended March 31, 2023. Kindly take this information on record. RPG LIFE SCIENCES LTD. - 532983 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of Related Party Transactions, in the format specified in the accounting standards for the half year ended March 31, 2023. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2023. Kindly take the above on record. RPG LIFE SCIENCES LTD. - 532983 - Corporate Action-Board approves Dividend
Recommended equity dividend of Rs. 12 per share of Rs. 8/- each (150%) for the financial year ended March 31, 2023, which will be paid to the shareholders within 30 days of declaration of the same at the ensuing Annual General Meeting.